Better Coronavirus Stock: Emergent Biosolutions vs. Regeneron
Shares of Emergent Biosolutions (NYSE: EBS) and Regeneron (NASDAQ: REGN) have risen sharply in 2020 thanks to potential coronavirus drugs in development, but that's where their similarities end. Is Emergent, a company with government contracts to produce vaccines for other drugmakers, a better stock to buy now than Regeneron, a biotechnology pioneer with several blockbuster drugs under its belt?
Over the past decade, Emergent Biosolutions has become the U.S. government's favorite contractor for infectious disease catastrophe preparation services. Instead of stockpiling vaccines for anthrax and other dangerous pathogens we're unlikely to encounter, the company's been tapped to help prepare for the COVID-19 threat that's already emerged.
Image source: Getty Images.
Source Fool.com
